Autoantibodies to Ca2+ binding protein Calnuc is a potential marker in colon cancer detection

Chen, Yao; Lin, Peter Ping; Qiu, Suimin; Peng, Xuan; Looi, Koksun; Farquhar, Marilyn G.; Zhang, Jian Ying

doi:10.3892/ijo.30.5.1137

Cited by 34 publications

(38 citation statements)

References 38 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Research by Chen and colleagues (99) investigating the reactivity to nucleobindin 1 (Calnuc) in sera from 52 patients with colon cancer, 39 patients with breast cancer, 16 patients with cervical cancer, 70 patients with esophageal cancer, 73 patients with gastric cancer, 62 patients with hepatic cancer, 104 patients with lung cancer, 14 patients with nasopharyngeal cancer, 17 patients with ovarian cancer, and 82 healthy controls showed no significantly higher Calnuc frequency in various cancer groups (4.7%) to healthy individuals (1.2%). When patients with colon cancer were investigated, Calnuc frequency was detected to be 11.5% in patients, which is significantly higher than the frequency mentioned in controls.…”

Section: Colon Cancermentioning

confidence: 99%

See 1 more Smart Citation

Serologic Autoantibodies as Diagnostic Cancer Biomarkers—A Review

Zaenker

Ziman

2013

Cancer Epidemiology, Biomarkers &Amp; Prevention

132

111

View full text Add to dashboard Cite

Current diagnostic techniques used for the early detection of cancers are successful but subject to detection bias. A recent focus lies in the development of more accurate diagnostic tools. An increase in serologic autoantibody levels has been shown to precede the development of cancer disease symptoms. Therefore, autoantibody levels in patient blood serum have been proposed as diagnostic biomarkers for early-stage diagnosis of cancers. Their clinical application has, however, been hindered by low sensitivity, specificity, and low predictive value scores. These scores have been shown to improve when panels of multiple diagnostic autoantibody biomarkers are used. A five-marker biomarker panel has been shown to increase the sensitivity of prostate cancer diagnosis to 95% as compared with 12.2% for prostate-specific antigen alone. New potential biomarker panels were also discovered for lung, colon, and stomach cancer diagnosis with sensitivity of 76%, 65.4%, and 50.8%, respectively. Studies in breast and liver cancer, however, seem to favor single markers, namely a-2-HS-glycoprotein and des-g-carboxyprothrombin with sensitivities of 79% and 89% for the early detection of the cancers. The aim of this review is to discuss the relevance of autoantibodies in cancer diagnosis and to outline the current methodologies used in the detection of autoantibodies. The review concludes with a discussion of the autoantibodies currently used in the diagnosis of cancers of the prostate, breast, lung, colon, stomach, and liver. A discussion of the potential future use of autoantibodies as diagnostic cancer biomarkers is also included in this review. Cancer Epidemiol Biomarkers Prev; 22(12); 2161-81. Ó2013 AACR.

show abstract

Section: Colon Cancermentioning

confidence: 99%

“…The same study achieved an increase to 65.4% sensitivity and 93.9% specificity when Calnuc was added to a TAA panel composed of c-myc, p53, G 2 /mitotic-specific cyclin-B1 (CCNB1), and G 1 -S-specific cyclin-D1 (CCND1; ref. 99). …”

Section: Colon Cancermentioning

confidence: 99%

Serologic Autoantibodies as Diagnostic Cancer Biomarkers—A Review

Zaenker

Ziman

2013

Cancer Epidemiology, Biomarkers &Amp; Prevention

132

111

View full text Add to dashboard Cite

show abstract

“…Tumor proteins can be affected by specific point mutations, misfolding, overexpression, aberrant glycosylation, truncation, or aberrant degradation (e.g. p53, HER2, NY-ESO1, or MUC1 (16,(21)(22)(23)(24)(25)). In fact, a number of tumorassociated autoantigens (TAAs) were identified previously in different studies involving autoantibody screening in CRC (26 -28).…”

Section: Colorectal Cancer (Crc)mentioning

confidence: 99%

Identification of Tumor-associated Autoantigens for the Diagnosis of Colorectal Cancer in Serum Using High Density Protein Microarrays

Babel

Barderas

Dı́az-Uriarte

et al. 2009

Molecular & Cellular Proteomics

146

143

View full text Add to dashboard Cite

There is a mounting evidence of the existence of autoantibodies associated to cancer progression. Antibodies are the target of choice for serum screening because of their stability and suitability for sensitive immunoassays. By using commercial protein microarrays containing 8000 human proteins, we examined 20 sera from colorectal cancer (CRC) patients and healthy subjects to identify autoantibody patterns and associated antigens. Fortythree proteins were differentially recognized by tumoral and reference sera (p value <0.04) in the protein microarrays. Five immunoreactive antigens, PIM1, MAPKAPK3, STK4, SRC, and FGFR4, showed the highest prevalence in cancer samples, whereas ACVR2B was more abundant in normal sera. Three of them, PIM1, MAPKAPK3, and ACVR2B, were used for further validation. A significant increase in the expression level of these antigens on CRC cell lines and colonic mucosa was confirmed by immunoblotting and immunohistochemistry on tissue microarrays. A diagnostic ELISA based on the combination of MAPKAPK3 and ACVR2B proteins yielded specificity and sensitivity values of 73.9 and 83.3% (area under the curve, 0.85), respectively, for CRC discrimination after using an independent sample set containing 94 sera representative of different stages of progression and control subjects. In summary, these studies confirmed the presence of specific autoantibodies for CRC and revealed new individual markers of disease (PIM1, MAPKAPK3, and ACVR2B) with the potential to diagnose CRC with higher specificity and sensitivity than previously reported serum biomarkers. Molecular & Cellular Proteomics 8:2382-2395, 2009.

show abstract

“…Although further research is required to study the underlying biochemistry of calnuc in this disease, it might act as a probable marker for detecting tumors of the stomach associated with lymph-node metastasis. Exploring the possibilities of calnuc as a tumor-associated antigen that can induce autoantibodies in human cancers has shown that though autoantibodies to calnuc are found in only 4.7% of human cancers, an exorbitant 11.5% of colon cancers carried autoantibodies to calnuc, when compared with 1.2% in normal individuals (46). Immunohistochemical studies have shown that 59.4% of colon cancers overexpress calnuc when compared with normal colon tissues.…”

Section: Calnuc-related Diseasesmentioning

confidence: 99%

Calnuc: Emerging roles in calcium signaling and human diseases

et al. 2010

View full text Add to dashboard Cite

SummaryCalnuc is a recently discovered multidomain protein with EF-hand calcium binding sites. Several studies have reported various interacting partners for calnuc and, therefore, also different sites of localization in the cell. It interacts with important molecules such as DNA, G protein, COX, and amyloid precursor protein among others in addition to being involved in stress response and trafficking. The immense possibilities (of various functions this protein might be involved in) implicate great future in medicine and physiology. Preliminary studies also implicate the possibility of calnuc being involved in some of the human diseases. These initial observations imply the functions that this protein might be involved in. This review emphasizes the importance of further research on this protein. IUBMBIUBMB Life, 62(6): [436][437][438][439][440][441][442][443][444][445][446] 2010

show abstract

Autoantibodies to Ca2+ binding protein Calnuc is a potential marker in colon cancer detection

Abstract: Abstract. Calnuc is a calcium (Ca 2+

Cited by 34 publications

References 38 publications

Serologic Autoantibodies as Diagnostic Cancer Biomarkers—A Review

Serologic Autoantibodies as Diagnostic Cancer Biomarkers—A Review

Identification of Tumor-associated Autoantigens for the Diagnosis of Colorectal Cancer in Serum Using High Density Protein Microarrays

Calnuc: Emerging roles in calcium signaling and human diseases

Contact Info

Product

Resources

About